KNOWING CAN BE AS SIMPLE AS CD123

BPDCN marker triad

Cell surface markers: vital to navigating hematologic cancer diagnosis

Cell surface markers are a critical diagnostic factor in identifying cancers, including hematologic malignancies. While these markers may overlap among different cancers, unique combinations can identify a cancer and offer potential therapeutic targets. Once uncovered, they contribute to a more precise and rapid diagnosis.1,2

These immunophenotypes can be identified via immunohistochemistry or flow cytometry. Diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) depends on markers including the key marker of CD123.2

The CD123 marker is expressed by a number of hematologic cancers, including BPDCN.3,4

CD123, as part of the signature marker triad in combination with CD4 and CD56, is a key marker in identifying BPDCN. Adding CD123 to initial hematologic panels is critical for an accurate diagnosis of BPDCN. Other diagnostic markers may include TCL1 and CD303 (BDCA2).1,2,4

CD123 SHOULD BE ADDED TO INITIAL HEMATOLOGIC DIAGNOSTIC PANELS.2

References:

  1. Reichard KK. Blastic plasmacytoid dendritic cell neoplasm: how do you distinguish it from acute myeloid leukemia? Surg Pathol Clin. 2013;6(4):743-765.
  2. Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174(2):188-202.
  3. Laribi K, Denizon N, Besançon A, et al. Blastic plasmacytoid dendritic cell neoplasm: from origin of the cell to targeted therapies. Biol Blood Marrow Transplant. 2016;22(8):1357-1367.
  4. Facchetti F, Cigognetti M, Fisogni S, Rossi G, Lonardi S, Vermi W. Neoplasms derived from plasmacytoid dendritic cells. Mod Pathol. 2016;29(2):98-111.